Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women

Lancet. 2011 Jul 16;378(9787):279-81. doi: 10.1016/S0140-6736(11)60878-7.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adenine / blood
  • Adenine / metabolism
  • Administration, Intravaginal
  • Administration, Oral
  • Africa South of the Sahara / epidemiology
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / blood
  • Anti-HIV Agents / metabolism*
  • Anti-Retroviral Agents / administration & dosage
  • Coitus
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / blood
  • Deoxycytidine / metabolism
  • Early Termination of Clinical Trials
  • Emtricitabine
  • Female
  • Gels
  • HIV Infections / epidemiology
  • HIV Infections / metabolism
  • HIV Infections / prevention & control*
  • Humans
  • Incidence
  • Organophosphonates / administration & dosage*
  • Organophosphonates / blood
  • Organophosphonates / metabolism*
  • Primary Prevention / methods*
  • Randomized Controlled Trials as Topic
  • Rectum / metabolism
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Tenofovir
  • Time Factors
  • Vagina / metabolism
  • Women's Health

Substances

  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • Gels
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Deoxycytidine
  • Tenofovir
  • Emtricitabine
  • Adenine